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SHORT COMMUfNICATION
Neurological illness following treatment with fludarabine
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Saummary Fludarabine is a comparatively new drug for the treatment of low-grade lymphoid malignancy.
This report describes five cases of unusual neurological illnesses occurring after treatment with fludarabine.
These suggest that caution should be exercised in patients receiving fludarabine who develop neurological
abnormalities, with prompt investigation and if necessary cessation of the drug.
The early trials of fludarabine given at high doses in the
treatment of acute leukaemia (up to 125 mg m~ daily for up
to 7 days) were complicated by severe neurological toxicity.
Patients developed progressive symptoms 1-2 months after
the completion of treatment, most commonly with optic
neuritis, cortical blindness, seizures and paralysis. The out-
come was fatal in some cases, with post-mortem findings of
widespread demyelination of the white matter and reactive
gliosis (Chun et al., 1986; Spriggs et al., 1986; Warrell &
Berman, 1986; Von Hoff, 1990). The combination of
fludarabine at a dose of 30 mg m2- for 5 days with
intermediate-dose cytosine arabinoside has also been reported
as causing occasional neurological disturbance, in some cases
with peripheral neuropathy, particularly in older patients and
those with renal impairment (Kornblau et al., 1993).
Use of fludarabine at lower doses for low-grade lymphoid
malignancy has not been associated with significant neuro-
toxicity to date. The majority of large studies report no
neurological side-effects (Keating et al., 1991; Puccio et al.,
1991; Whelan et al., 1991). This report describes neurological
abnormalities which arose in five patients receiving flud-
arabine at conventional doses for low-grade lymphoid malig-
nancies, in one case with a fatal outcome.
Case reports
Case I
A 45-year old woman presented with stage IV centroblas-
tic-centrocytic follicular lymphoma. Treatment with fludara-
bine at a dose of 25 mg m2 daily for 5 days at intervals of 4
weeks was given following unsatisfactory responses to
chlorambucil and cyclophosphamide/doxorubicin/vincristine
prednisolone (CHOP).
The first cycle of fludarabine treatment was complicated by
the sudden onset of severe generalised headache 2 h after the
first dose. There were no neurological signs on examination
and a computerised tomographic (CT) scan of the brain with
contrast enhancement was normal, as was examination of the
cerebrospinal fluid (CSF). Fludarabine was continued, during
which time the headaches persisted, finally resolving 2 weeks
after the start of treatment. A similar headache of lesser
intensity occurred on the third day of chemotherapy in the
second cycle and persisted for 1 week.
The third cycle of chemotherapy was associated with only
mild headache, but on the tenth day from the start of
treatment the patient noticed recurrent numbness in the right
hand, subsequently spreading to involve the right arm, face
and leg. On examination she had a right-sided hemiparesis,
hyper-reflexia, extensor plantar response and faciobrachial
sensory impairment to all modalities. A contrast-enhanced
CT scan was normal, as was examination of the CSF. How-
ever, a magnetic resonance scan showed increased signal on
variable echo images of the left caudate nucleus, corona
radiata and deep white matter, and angiography demon-
strated marked narrowing of the left internal carotid artery
with no filling of the anterior cerebral artery on that side
(Figure 1). Investigations for a systemic vasculitis and
coagulopathy were negative. A brain biopsy was carried out
with resection of the left temporal pole but no histological
abnormality was present.
The patient's condition deteriorated progressively despite
empirical treatment with intravenous dexamethasone (32 mg
daily) and therapeutic heparinisation, with worsening of the
signs on the right side and subsequent involvement of the left
as well. She died 5 weeks after the last dose of fludarabine.
At post-mortem the brain showed multifocal acute infarction
and the cerebral arteries showed extensive mural thickening.
Histology confirmed almost complete luminal occlusion by
an intimal fibrous proliferation without associated lipid
deposition. The media and adventitia of all vessels were
normal with no evidence of vasculitis. No lymphoma was
present in the brain or cerebral vessels.
Case 2
A 41-year-old woman presented with stage IV T-zone lym-
phoma. She was initially treated with fludarabine 25 mg m-'
daily for 5 days at 4 weekly intervals with a good response.
On day 7 of the seventh cycle she developed severe general-
ised headache in association with right hemiparesis and
hemisensory loss. These resolved spontaneously over the
course of 1 week, after which neurological examination was
Fugwe 1 Left carotid angiogram of case 1. Lateral view showing
marked narrowing of the internal carotid artery. with no filling of
the anterior cerebral.
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normal. CT scanning and examination of the CSF were not
performed. No further treatment with fludarabine was given.
One year later the patient developed high-grade T-cell lym-
phoma in the bone marrow, for which she was treated with
combination chemotherapy followed by high-dose cyclophos-
phamide and total body irradiation with peripheral blood
progenitor cell rescue. She remains in complete remission and
has had no further episodes of neurological disturbance.
Case 3
A 52-year-old man had been treated 9 years previously for
centroblastic-centrocytic follicular lymphoma. Second remis-
sion was consolidated with high-dose cyclophosphamide and
total body irradiation with autologous bone marrow rescue.
Asymptomatic bone marrow recurrence was diagnosed 3
years after the myeloablative treatment.
Two years later the patient developed arthralgia, mouth
ulcers and iritis. A clinical diagnosis was made of Behget's
syndrome, which was complicated by a brain-stem stroke
resulting in left hemiparesis, vertigo, nausea and dysarthria.
His condition improved on treatment with prednisolone and
azathioprine, leaving only minimal residual signs and no
subjective weakness.
Four years after detection of the recurrence of lymphoma
in the bone marrow the patient developed peripheral lym-
phadenopathy and became neutropenic and thrombocyto-
penic. This was not improved by cessation of azathioprine
treatment or by adminstration ofprednisolone and chloram-
bucil. Treatment with fludarabine 25 mgm-2 daily for 5 days
was commenced while the patient continued taking pred-
nisolone 40 mg daily. On the 19th day ofthe second cycle the
patient developed paraesthesie and weakness on the left
side, identical to his symptoms at the time of his previous
cerebrovascular accdent. He attended hospital 5 days later,
by which time the symptoms had resolved, and on examina-
tion no new neurological signs could be elicited. A contrast-
enhanced CT scan ofthe brain was normal. The blood count
showed marked improvement and a third cycle of treatment
was therefore given 1 week later. On day 25 the left-sided
weakness and paraesthesiae recurred, only to resolve 3 days
later.
Case 4
A 68-year-old man presented with a stage IV low-grade
T-ell lymphoma of Lennert's type. He was treated with
fludarabine 25 mg m2 daily for 5 days at 4 week intervals
with a satisfactory response after the first cycle. Twelve days
from the start of the second cycle the patient noticed
heaviness of the hands and feet, with marked limb weakness.
On examination he showed global loss of power in the limbs
and areflexia. Bulbar function and sensation were unaffected.
A contrast-enhanced CT scan ofthe brain was normal, but
excamination of the CSF showed an elevated protein level at
0.93 g 1'. No oligoclonal bands were detectable. Cytology of
the CSF was normal and microbiology negative. Nerve con-
duction studies showed abnormal small sensory action poten-
tials and only marginally reduced motor conduction velocity.
The patient's symptoms gradually worsened with progres-
sive weakness and breathlssness. Treatment with intra-
venous immunoglobulin 0.6 gkg-' on three consecutive days
was without effect, and repeat nerve conduction studies 2
weeks after the first showed clear deterioration with findings
suggestive of a patchy diffuse demyelinating neuropathy. The
vital capacity, however, remained above 21, bulbar function
was intact and a 24 h ECG recording showed no significant
dysrhythmias. The weakness showed gradual spontaneous
improvement from 6 weeks after the last dose of chemo-
therapy and had resolved completely 4 months later.
Computerised tomographic scans showed almost complete
resolution of the previous lymphadenopathy, and a bone
marrow biopsy showed no evidence of lymphoma. The
patient was observed without further therapy and remains
well 12 months from the start of treatment.
Case 5
A 59-year-old man with chronic lymphatic leukaemia had
been observed without requiring treatment for 3 years from
the time of diagnosis on a routine blood count. When he
developed increasing lymphadenopathy and anaemia
chlorambucil was given with only minimal response. Further
treatment with fludarabine 25 mg m2 daily for 5 days was
therefore given, but on the 12th day from the start of this he
developed breathlessness and a dry cough with a chest
radiograph showing bilateral perihilar interstitial infiltrates
consistent with Pnewnocystis carinii pneumonia. He was
treated with high-dose co-trimoxazole and his condition
steadily improved. He was also given vitamin B12 and folic
acid supplements in view of the depression of erythropoiesis.
On the 16th day after the first dose of fludarabine he
developed a marked tremor with unsteadiness of gait. On
examination he had a postural tremor, global weakness of all
four limbs, areflexia and impaired joint position sense. A
contrast-enhanced CT scan of the brain was normal, as was
examination of the CSF. Nerve conduction studies showed
marked slowing of motor conduction velocities in the lower
limb without any abnormality of compound muscle action
potentials. The sensory action potential amplitudes were nor-
mal. The findings were suggestive of a predominantly motor
demyelinating peripheral neuropathy. He made an uneventful
recovery with conservative management and the neurological
signs resolved after I month. He was subsequently observed
without active treatment for the leukaemia once again, and
treated with cyclosporin A for red cell aplasia. He remains
well I year later.
Dbcsion
Fludarabine given at a dose of 25 mgm-2 as an intravenous
bolus for five consecutive days is generally very well
tolerated. Although myelosuppression can occasionally be
severe and infectious compLications occur, in general the
treatment is of low toxicity. One hundred and forty patients
have received fludarabine at St Bartholomew's Hospital in
the last 3 years, so that five cases reflect an uncommon
problem.
There are few previous reports of neurotoxicity associated
with the use of fludarabine at these doses. One study
reported reversible grade III toxicity with visual and auditory
changes in up to 10% ofsubjects (Hochster et al., 1992) and
one report described severe symptoms developing in a patient
with cerebral lymphoma (Merkel et al., 1986). There are two
case reports of reversible motor deficits and white matter
abnormalities on MRI scans which bear some resemblance to
cases 1, 2 and 3 in this account (Cohen et al., 1993), and the
reports ofperipheral neuropathy seen in patients treated with
the combination of fludarabine and cytosine arabinoside
show considerable similarity to cases 4 and 5 (Kornblau et
al., 1993).
It is not certain that these events were directly attributable
to treatment with fludarabine: patients with lymphoma are
subject to a variety of neurological complications (Henson &
Urich, 1982), and peripheral demyelination is among those
commonly seen. It would be difficult to postulate a common
mechanism by which these vanous syndromes might have
arisen. However, the temporal relationship to the administra-
tion of fludarabine is striking, particularly in cases 1 and 2,
in whom the headaches arose during the week of treatment,
and case 3, in whom the symptoms of a previous cerebrovas-
cular event appred to be recalled by each cycle of treat-
ment, without other findings to suggest recurrent infarction.
It is possible that the demyelinating neuropathy ofcase 4 was
coincidental or related to the lymphoma, although this was
regresing at the time the neuropathy developed. It could also
be argued that in case 5 the neuropathy arose as a complica-
tion of the chest infection, but this seems less likely as the
delay between the two events was only 4 days.
The histological findings at autopsy in case 1 were highly968 P.W.M. JOHNSON et al.
unusual, with vascular intimal hyperplasia suggestive of
moya-moya' disease (Suzuki & Takaku, 1969), although the
angiographic appearances were not typical. While this also
might be related to the malignancy, there are no previous
similar cases, and the absence of any cerebral lymphoma at
post-mortem makes it unlikely. The development of severe
headaches is an unusual side-effect of treatment with
fludarabine (or indeed any chemotherapy), but it seems quite
probable that they were related to the onset of the injury.
These cases suggest that caution should be exercised in the
administration of fludarabine at conventional doses, and
adverse neurological events carefully characterised and
reported. Patients with pre-existing neurological deficits could
be subject to deterioration of their condition although this
may well prove reversible. The onset of severe headache
should be a cause for concern in the light of this report, and
consideration given to stopping treatment. Full neurological
assessment must be carried out promptly in all cases, includ-
ing detailed imaging of the brain, examination of the CSF
and where indicated vascular and electrophysiological
studies.
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